Law360, New York (October 09, 2009) -- Institutional investor Amalgamated Bank is competing with an individual shareholder over who will lead a consolidated derivative lawsuit alleging that Pfizer Inc.'s executives harmed the company by promoting prescription drugs for unapproved, off-label uses.
At least eight derivative complaints have been filed in the U.S. District Court for the Southern District of New York since Pfizer agreed last month to pay a record $2.3...
